おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Orna Therapeutics
company
About
Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $80M
- Industries
- Biotechnology,Medical,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2019
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease.The company's proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.Orna Therapeutics was established in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$80M
Orna Therapeutics has raised a total of
$80M
in funding over 2 rounds. Their latest funding was raised on
Feb 24, 2021 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 24, 2021 | Series A | $80M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Orna Therapeutics is funded by 1 investors.
Kite Pharma
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Kite Pharma
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
